Exploring Biomarkers and Pharmacotherapies for Substance Use Disorders
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 November 2024 | Viewed by 165
Special Issue Editors
Interests: animal models; addiction; psychiatry; pharmacology; neurological diseases
Interests: neuropharmacology; psychiatric disorders; substance use disorders; clinical trials; animal models
Interests: endocannabinoid system; psychiatry; animal models; alcohol addiction; cannabis use disorders
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
"Exploring Biomarkers and Pharmacotherapies for Substance Use Disorders" is a Special Issue with a focused objective of identifying behavioral, genetic, and epigenetic mechanisms involved in drug addiction, as well as potential new pharmacological agents for treating these disorders in both humans and animal models.
Substance Use Disorders (SUD), encompassing alcohol, cannabis, stimulants, and other substances, pose a significant global health burden, impacting millions of people worldwide. Despite the profound consequences of these disorders on individuals, families, and societies, effective and precise diagnostic and therapeutic approaches remain limited. Therefore, it is imperative to identify the specific biomarkers associated with different stages of the disease, aiming to deepen our understanding of the underlying alterations and explore effective pharmacological interventions.
In this context, research focusing on behavioral, brain, and peripheral alterations in both human subjects and animal models, simulating various stages of SUD, is highly encouraged. These alterations may arise from drug exposure during adulthood, adolescence, or even the perinatal period (gestation and lactation). Additionally, studies that delve into the pharmacological aspects, demonstrating the modulation of these alterations, are also welcomed in this Special Issue. To summarize, this Special Issue aims to cover all the essential aspects that can contribute to our enhanced comprehension of the biological basis of addiction and the identification of pharmacological interventions for treating SUD.
Dr. Ani Gasparyan
Dr. Daniela Navarro
Prof. Dr. Jorge Manzanares
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
